hVIVO plc Exercise of Share Options (6331Z)
14 January 2020 - 12:39AM
UK Regulatory
TIDMHVO
RNS Number : 6331Z
hVIVO plc
13 January 2020
HVIVO plc
("hVIVO" or the "Company")
Exercise of Share Options
London, UK, 13 January 2020: hVIVO plc (AIM: HVO), an industry
leading clinical development services business supporting product
development for companies developing antivirals, vaccines and
respiratory therapeutics, announces that, following the exercise of
employee share options by an ex-employee, application has been made
to AIM for the admission of 37,941 new ordinary shares of 5 pence
each (the "New Ordinary Shares"). Admission to trading on AIM of
the New Ordinary Shares ("Admission"), which will rank pari passu
in all respects with the Company's existing shares in issue, is
expected to occur on 17 January 2020.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 83,637,003 and this figure may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
For further information please contact:
hVIVO plc
Anesh Patel (Interim Finance Director & Company Secretary) +44 207 756 1300
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited +44 207 260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 100
Notes to Editors:
hVIVO is an industry leading clinical development services
business supporting product development for customers developing
antivirals, vaccines and respiratory therapeutics. Leveraging human
disease models in human rhinovirus (HRV), RSV, Influenza (Flu)
Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO
platform illuminates the entire disease cycle in people from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted 56 clinical studies and inoculated over 2900
volunteers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEBXGDBLXBDGGX
(END) Dow Jones Newswires
January 13, 2020 08:39 ET (13:39 GMT)
hVIVO (AQSE:HVO.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
hVIVO (AQSE:HVO.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
